On December 17, the U.S. Food and Drug Administration (FDA) finalized its long-awaited guidance on the “Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices,” ...
Key opportunities in the real-world evidence solutions market include integration of AI and advanced analytics, precision ...
Target RWE, a leader in advancing modern evidence generation for complex clinical and regulatory challenges, today announced the presentation of compelling new findings from the REPATHA-CE study of ...
In January 2026, FDA issued draft guidance that expanded the potential use of real-world evidence (RWE) during the clinical ...
In today’s ACT Brief, we highlight where AI is delivering real gains in protocol development, how geopolitical disruption is ...
New research by Tufts Center for the Study of Drug Development (CSDD) documents the growing importance of real-world data ...
Real-world data (RWD) has come a long way. Today, it’s all about turning that data into real-world evidence (RWE) that shapes regulatory decisions, payer discussions, and clinical practice. This ...
Real-world evidence can enable improved patient outcomes, but Europe must strengthen RWD infrastructure and policy frameworks to meaningfully inform high-quality decision-making. RWE initiatives like ...
Fifteen top US Food and Drug Administration (FDA) officials published an article in the New England Journal of Medicine on Thursday calling into question some of the potential uses of real-world ...
The HealthVerity agreement is the latest in a series of data partnerships through which Thermo Fisher has been expanding its RWD infrastructure. Earlier this year, the company announced a strategic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results